

Arnulf Ferlitsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4924134/publications.pdf>

Version: 2024-02-01

99
papers

4,689
citations

81743

39
h-index

102304

66
g-index

101
all docs

101
docs citations

101
times ranked

4594
citing authors

#	ARTICLE	IF	CITATIONS
1	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
2	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 723-732.	0.2	105
3	Impact of <i>HSD17B13 rs72613567</i> genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	1.9	20
4	Noninvasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , 2020, 40, 894-904.	1.9	19
5	Combination of phosphodiesterase inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , 2020, 40, 2228-2241.	1.9	9
6	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1619-1627.	1.4	12
7	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
8	von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020, 14, 218-224.	1.4	9
9	DIFFERENCES IN BOWEL PREPARATION QUALITY BETWEEN IN- AND OUTPATIENTS UNDERGOING SCREENING COLONOSCOPY. <i>Endoscopy</i> , 2020, 52, .	1.0	0
10	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
11	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 127-135.	1.9	39
12	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 2374-2385.	1.9	47
13	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	1.6	18
14	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	1.1	10
15	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	1.1	8
16	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.4	23
17	Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 496-502.	0.5	25
18	Impact of high-volume, intermediate-volume and low-volume bowel preparation on colonoscopy quality and patient satisfaction: An observational study. <i>United European Gastroenterology Journal</i> , 2019, 7, 114-124.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019, 49, 201-211.	1.8	16
20	The value of different CT-based methods for diagnosing sarcopenia and predicting mortality in patients with cirrhosis. , 2019, 57, .		0
21	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a doseâ€response study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1162-1169.	1.9	33
22	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 966-979.	1.9	41
23	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	1.9	31
24	Editorial: getting bullish about portal hypertensionâ€™ chronic treatment with oral taurine? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 534-535.	1.9	0
25	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 980-988.	1.9	78
26	Editorial: optimal dose of carvedilol in portal hypertensionâ€™ nearly there. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1329-1330.	1.9	0
27	ePTFEâ€™TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	1.9	28
28	Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 86-94.	1.9	36
29	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. <i>Hepatology</i> , 2018, 67, 1516-1530.	3.6	39
30	Editorial: surviving your genesâ€™ the role of <i>PNPLA3</i> variation in endâ€stage liver disease. Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 775-776.	1.9	0
31	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	0.7	11
32	Impact of patatinâ€™like phospholipase domain containing <i>rs738409</i> genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 451-459.	1.9	26
33	Management of Coagulopathy during Bleeding and Invasive Procedures in Patients with Liver Failure. <i>Visceral Medicine</i> , 2018, 34, 254-258.	0.5	19
34	Liver disease in adults with α 1-antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	1.6	23
35	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding â€™ A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	1.1	20
36	Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosisâ€™ Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1537-1538.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wiener Klinische Wochenschrift, 2018, 130, 446-455.	1.0	41
38	IMPROVING THE ADENOMA DETECTION RATE CONTINUOUSLY: IS IT WORTH THE EFFORT?. Endoscopy, 2018, 50, .	1.0	0
39	Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2018, 56, .	0.2	0
40	The impact of hepatic steatosis on portal hypertension. Zeitschrift Fur Gastroenterologie, 2018, 56, .	0.2	0
41	Prevalence and Resistance Rates of Infections with Enterococci in Patients with Cirrhosis. , 2018, 56, .		0
42	Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information. , 2018, 56, .		0
43	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. , 2018, 56, .		0
44	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 184-190.	1.4	17
45	Interferon-free regimens improve portal hypertension and histological necroinflammation in <scp>HIV</scp>/<scp>HCV</scp> patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 139-149.	1.9	83
46	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	0.6	13
47	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.0	111
48	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease, 2017, 49, 1360-1367.	0.4	28
49	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance. Investigative Radiology, 2017, 52, 462-469.	3.5	14
50	Serum bile acids as marker for acute decompensation and acute-to-chronic liver failure in patients with non-cholestatic cirrhosis. Liver International, 2017, 37, 224-231.	1.9	47
51	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener Klinische Wochenschrift, 2017, 129, 8-15.	1.0	44
52	The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver International, 2016, 36, 1649-1656.	1.9	10
53	Efficacy and safety of bovine activated factors IIa/VIIa/IXa/Xa in patients with active gastrointestinal bleeding: a proof of concept study. Endoscopy, 2016, 48, 380-384.	1.0	1
54	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. Journal of Hepatology, 2016, 65, 692-699.	1.8	245

#	ARTICLE	IF	CITATIONS
55	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.	0.4	1
56	Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. <i>British Journal of Cancer</i> , 2016, 115, 1421-1429.	2.9	29
57	The profile of platelet α -granule released molecules affects postoperative liver regeneration. <i>Hepatology</i> , 2016, 63, 1675-1688.	3.6	67
58	Endoscopic versus surgical management of biliary complications – Outcome analysis after 1188 orthotopic liver transplantations. <i>Digestive and Liver Disease</i> , 2016, 48, 1323-1329.	0.4	10
59	The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test. <i>PLoS ONE</i> , 2016, 11, e0149230.	1.1	58
60	Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 707-718.	1.9	44
61	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1657-1665.	1.4	37
62	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. <i>Liver International</i> , 2015, 35, 2115-2120.	1.9	54
63	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2340-2349.	0.7	23
64	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. <i>Digestive and Liver Disease</i> , 2015, 47, 144-150.	0.4	43
65	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015, 35, 2121-2128.	1.9	72
66	High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. <i>Endoscopy</i> , 2015, 47, 207-216.	1.0	25
67	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 381-390.	1.9	111
68	Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?. <i>Endoscopy</i> , 2015, 47, 898-902.	1.0	23
69	A Greater Proportion of Liver Transplant Candidates Have Colorectal Neoplasia Than in the Healthy Screening Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 956-962.	2.4	15
70	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015, 277, 903-912.	3.6	60
71	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015, 35, 876-885.	1.9	32
72	Evaluation of Portal Hypertension and Varices by Acoustic Radiation Force Impulse Imaging of the Liver Compared to Transient Elastography and AST to Platelet Ratio Index. <i>Ultraschall in Der Medizin</i> , 2014, 35, 528-533.	0.8	75

#	ARTICLE	IF	CITATIONS
73	Endoscopic imaging of the vermiform appendix (with video). <i>Gastrointestinal Endoscopy</i> , 2014, 80, 1156-1160.	0.5	5
74	Nonselective β_2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	0.6	336
75	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 544-549.	1.8	43
76	Liver Biopsy-Transjugular. <i>Clinical Liver Disease</i> , 2014, 4, 113-115.	1.0	5
77	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	1.1	55
78	Reply. <i>Hepatology</i> , 2013, 58, 1189-1190.	3.6	0
79	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 911-921.	1.8	269
80	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 200-219.	1.0	43
81	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013, 62, 1634-1641.	6.1	275
82	A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV/HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1327-1334.	0.6	27
83	Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , 2012, 56, 1439-1447.	3.6	158
84	Letter: sorafenib in portal hypertension – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 994-995.	1.9	1
85	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. <i>European Journal of Radiology</i> , 2012, 81, 4112-4118.	1.2	156
86	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography – a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 395-402.	1.0	93
87	Non-selective β_2 -blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. <i>Journal of Gastroenterology</i> , 2012, 47, 561-568.	2.3	97
88	The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 83-91.	1.9	83
89	Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 602-608.e1.	2.4	57
90	von Willebrand Factor Antigen: A Novel On-Treatment Predictor of Response to Antiviral Therapy in Chronic Hepatitis C Genotypes 1 and 4. <i>Antiviral Therapy</i> , 2010, 15, 831-839.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Effect of virtual endoscopy simulator training on performance of upper gastrointestinal endoscopy in patients: a randomized controlled trial. <i>Endoscopy</i> , 2010, 42, 1049-1056.	1.0	63
92	A novel endoscopic device for repeated right-side colonic access during colonoscopy (with video). <i>Gastrointestinal Endoscopy</i> , 2010, 71, 1052-1055.	0.5	1
93	6-Thioguanine Associated Nodular Regenerative Hyperplasia in Patients With Inflammatory Bowel Disease May Induce Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2007, 102, 2495-2503.	0.2	80
94	Prescintigraphic morphine application for abdominal adenocarcinoma imaging, with technetium-99m methoxy isobutyl isonitrile. <i>Hellenic Journal of Nuclear Medicine</i> , 2007, 10, 14-8.	0.2	1
95	Safety and Efficacy of Endoscopic Balloon Dilatation for Treatment of Crohn's Disease Strictures. <i>Endoscopy</i> , 2006, 38, 483-487.	1.0	100
96	Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. <i>Critical Care Medicine</i> , 2005, 33, 2028-2033.	0.4	29
97	Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 49-55.	1.9	18
98	Evaluation of a Virtual Endoscopy Simulator for Training in Gastrointestinal Endoscopy. <i>Endoscopy</i> , 2002, 34, 698-702.	1.0	162
99	Diamond Stents for Palliation of Malignant Bile Duct Obstruction: A Prospective Multicenter Evaluation. <i>Endoscopy</i> , 2001, 33, 645-650.	1.0	44